Skip to main
  1. Stocks
  2. Zimmer Biomet Hlds
  3. Forecast
ZBH

ZBH Stock Forecast & Price Target

ZBH Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 24%
Buy 24%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Zimmer Biomet Holdings is viewed positively because its core reconstructive franchise remains anchored by leading share in the U.S., Europe, and Japan, while large joints still drive roughly two-thirds of revenue and a diversified second leg spans extremities, trauma, and sports medicine. The outlook is strengthened by a broad robotic portfolio and the pulled-forward mid-2027 launch of Monogram, which surgeons described as potentially disruptive through faster procedures, fewer trays, better accuracy, and support for cementless knee adoption, with 2027 EPS estimated at $8.91 and 2027 organic growth modeled at 3.5%. Additional support comes from the commercial transition tracking well, Paragon 28 growing above recent organic rates, and margin-accretive innovation such as iodine-coated hips, all of which reinforce the company’s transformation toward improved fundamentals.

Bears say

Zimmer Biomet Holdings is exposed to a downside case driven by deferred elective procedures from COVID-related capacity constraints, which can pressure large-joint volumes and limit near-term revenue recovery. Its outlook is also weakened by slower adoption of ROSA and recently launched products such as PERSONA, where capital constraints, competition, and weaker pull-through to implants could reduce expected operating leverage and prevent OM expansion toward +30%. Additional risks include disruption from the 2022 spine/dental spin-off, pricing pressure such as China VBP, and less operating leverage than planned, which together could sustain a declining growth environment.

ZBH has been analyzed by 17 analysts, with a consensus rating of Buy. 24% of analysts recommend a Strong Buy, 24% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.

ZBH Analyst Forecast & Price Prediction

Get the latest ZBH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZBH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zimmer Biomet Hlds (ZBH) Forecast

Analysts have given ZBH a Buy based on their latest research and market trends.

According to 17 analysts, ZBH has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zimmer Biomet Hlds (ZBH)


ZBH Analyst Forecast & Price Prediction

Get the latest ZBH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZBH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZBH stock data and trends